litoxetine
Litoxetine (developmental code names SL 81-0385, IXA-001) is an antidepressant which was under clinical development for the treatment of depression in the early 1990s but was never marketed. It acts as a potent serotonin reuptake inhibitor (Ki for SERTTooltip serotonin transporter = 7 nM) and modest 5-HT3 receptor antagonist (Ki = 315 nM). It has antiemetic activity, and unlike the selective serotonin reuptake inhibitors (SSRIs), appears to have a negligible incidence of nausea and vomiting. The drug is structurally related to indalpine. Development of litoxetine for depression was apparently ceased in the late 1990s. However, as of March 2017, development of litoxetine has been reinitiated and the drug is now in the phase II stage for the treatment of urinary incontinence. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Earliest trial started Apr 3, 2018 (NCT03397771)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Serotonin 3a (5-HT3a) receptorINHIBITOR
HTR3A inhibitor
Chemistry & pharmacology
SMILES
c1ccc2cc(COC3CCNCC3)ccc2c1- Mol. weight
- 241.33 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL471036 ↗
- WikipediaLitoxetine ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03397771 | Phase 1/Phase 2 (Phase 2) | Apr 3, 2018 | Ixaltis SA |
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ixaltis SA | For profit | 1 | 1 | 1 | 2018 |